A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
← catalyst calendarNCT07152002 · readout ≤ 103 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
144estimated
Sites
3
Countries
Singapore, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-28 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight or Obesity
- Healthy
Interventions
- Drug: LY4064912
- Drug: LY4064912
- Drug: Placebo
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
measured Postdose to Approximately Week 27
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed